Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

Zhejiang Wolwo Bio-Pharmaceutical announced that, due to the dissolution of the marriage between actual controller Hu Gengxi and Yanni Chen and the subsequent division of property, the company's actual controller will change from Hu Gengxi and Yanni Chen to Yanni Chen, while the controlling shareholder remains Zhejiang Wolwo Management Consulting. Shares directly held by Hu Gengxi remain his personal property, his 100% equity in Mingchen Investment goes to his grandson Niu Chen'an, and the 100% equity in Hong Kong Haorui held by Yanni Chen remains her personal property. Mingchen Investment and Hong Kong Haorui hold 33.87% and 40% of Wolwo Consulting respectively, and Wolwo Consulting holds 38.86% of Zhejiang Wolwo Bio-Pharmaceutical. On the same day, Hu Gengxi resigned from all positions including chairman for personal reasons and no longer serves as legal representative. Before a new chairman is elected, Yanni Chen will perform the duties of chairman. In the first half of 2026, Zhejiang Wolwo Bio-Pharmaceutical achieved operating revenue of 514 million yuan, up 6.18% year on year, and net profit of 213 million yuan, up 20.59% year on year.

Wolwo Bio released its 2026 interim report, showing total operating revenue of 514 million yuan and net profit attributable to the parent company of 213 million yuan. Net cash inflow from operating activities was 190 million yuan, a decrease of 11.008 million yuan compared with the same period last year, down 5.49 percent year on year. The company's asset-liability ratio was 7.71 percent, gross margin was 95.29 percent, return on equity was 7.75 percent, and diluted earnings per share was 0.41 yuan. The number of shareholders was 35,300, and the top ten shareholders held 54.76 percent of the total share capital.

Zhejiang Wolwo Bio-Pharmaceutical announced that its Class 1 new drug, a cat hair film agent, has received approval from the National Medical Products Administration to conduct clinical trials for adult patients with allergic rhinitis related to cat hair and dander sensitization. The product is a Class 1 therapeutic biological product in the form of a sublingual film. It will work in coordination with the already marketed cat hair and dander allergen skin prick test solution to provide a combined diagnostic and therapeutic solution, and will complement the dust mite drops and mugwort pollen allergen sublingual drops. As of the announcement date, no other domestic company has obtained a registration certificate for this product. The company cautioned that subsequent stages, including Phase I to Phase III clinical trials and marketing authorization applications, are still required and involve uncertainty.

Zhejiang Wolwo Bio-technology announced that the clinical trial application for its chemical Class 1 new drug S01D tablets has been formally accepted by the National Medical Products Administration. The drug is indicated for adult patients with drug-resistant pulmonary tuberculosis and is a Class 1 chemical drug with a new molecular entity and novel mechanism. Non-clinical studies suggest superior activity against Mycobacterium tuberculosis. As of the disclosure date, no identical chemical drug has been approved for marketing domestically or internationally. According to regulations, the Center for Drug Evaluation will decide within 60 days of acceptance whether to approve the clinical trial. Subsequent steps, including Phase I, II, and III clinical trials and the marketing authorization application, must still be completed, and outcomes are subject to significant uncertainty. The company stated that this acceptance marks an important R&D milestone in the field of drug-resistant pulmonary tuberculosis.

The drug clinical trial application for Human Umbilical Cord Mesenchymal Stem Cell Type II Injection, submitted by Zhejiang Wolwo Stem Cell Technology, an indirectly controlled subsidiary of Wolwo Bio, has been formally accepted by the National Medical Products Administration. The product is a Class 1 therapeutic biological product, indicated for sepsis and/or septic shock. Currently, no similar mesenchymal stem cell drug has been approved for marketing either domestically or internationally. The company stated that this acceptance marks an important R&D milestone in the stem cell drug field. In the first quarter of 2026, Wolwo Bio achieved revenue of 253 million yuan and net profit attributable to the parent of 119 million yuan.